ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

ImmunityBio Inc. (NASDAQ:IBRX) shares are up on Monday following the company’s announcement of significant revenue growth. • ImmunityBio stock is challenging resistance. Why are IBRX shares at highs?The stock has jumped around 55% over the last month, thanks to investor interest after preliminary earnings and several strategic partnerships.The company’s lead drug, Anktiva, is approved in the U.S. and several international markets for BCG-unresponsive NMIBC with carcinoma in situ.700% Sales JumpImmunityBio r ...